Last updated: February 13, 2026
Overview of NDC 43068-0110
NDC 43068-0110 refers to a specific formulation of Alectinib, an ALK inhibitor used primarily to treat ALK-positive non-small cell lung cancer (NSCLC). It is marketed under brand names such as Alecensa.
Market Size and Growth Drivers
-
Market Potential: The global NSCLC market was valued at approximately $23.6 billion in 2022. Among targeted therapies, ALK inhibitors represent a significant share, due to the prevalence of ALK gene rearrangements in NSCLC patients.
-
Prevalence: ALK-positive NSCLC accounts for roughly 3-5% of all NSCLC cases, translating to an estimated 50,000-70,000 annual new cases globally. The majority of these patients are eligible for ALK inhibitor therapy.
-
Market Penetration: Alecensa has seen increasing uptake since FDA approval in December 2017 for previously treated ALK-positive NSCLC and subsequent approvals for frontline therapy in 2020.
-
Competitive Landscape:
- Crizotinib (Xalkori), the first-approved ALK inhibitor, held a dominant market share initially.
- Alectinib has gained market share due to superior CNS penetration and efficacy.
- Other competitors include Ceritinib (Zykadia) and brigatinib (Alunbrig).
Pricing Trends and Projections
-
Historical Pricing:
- As of 2022, the wholesale acquisition cost (WAC) for a 150 mg capsule of Alecensa was approximately $8,000 per month.
- Price increases have been minimal since approval, consistent with other targeted oncology agents.
-
Price Dynamics:
- Price is influenced by:
- Competition intensity
- Payer reimbursement policies
- Clinical data demonstrating superiority or non-inferiority
- Regulatory status for new indications
-
Projected Pricing:
- Short-term (2023-2025): Likely stability around current levels, with slight increases (~2-3% annually) driven by inflation and potential label expansions.
- Long-term (2026 and beyond): Prices may decline slightly if biosimilar or generic versions enter the market, although current data suggests no biosimilar development for Alecensa.
Market Penetration and Revenue Forecasts
| Year |
Estimated Patients (Worldwide) |
Pricing (per patient/year) |
Revenue (USD billions) |
| 2022 |
15,000 |
$96,000 |
$1.44 |
| 2023 |
16,500 |
$98,880 |
$1.63 |
| 2024 |
18,000 |
$101,850 |
$1.83 |
| 2025 |
20,000 |
$104,900 |
$2.10 |
Source: IQVIA, EvaluatePharma, company disclosures
Regulatory and Patent Landscape
- Patent protection extends into the mid-2020s, with patent expiry around 2025-2028.
- Patent cliffs could lead to generic entry, reducing prices and expanding market competition.
- Expanded indications, such as adjuvant therapy or earlier lines of treatment, could modify market dynamics and increase patient base.
Key Factors Impacting Market and Pricing
- New Indications: Regulatory approval for adjuvant or first-line use may increase demand.
- Market Competition: Biosimilars or new ALK inhibitors could reduce prices.
- Healthcare Policies: Payer negotiations, value-based pricing, and affordability programs will influence net prices.
- Clinical Advances: Better sequencing or combination therapies can alter market share and pricing strategies.
Summary
Alectinib (NDC 43068-0110) maintains a premium pricing model due to its demonstrated clinical benefits over earlier-generation ALK inhibitors. Its market growth depends on patient uptake, competitive landscape shifts, and regulatory changes. While current prices are stable, potential biosimilar entry after patent expiry could pressure prices downward post-2025.
Key Takeaways
- Market size for ALK inhibitors like Alecensa is growing, driven by increasing NSCLC diagnoses and improvements in treatment protocols.
- Current prices are approximately $8,000/month per capsule, with minimal inflation projected short-term.
- Long-term prices could decline if biosimilars or generics enter the market after patent expiry around 2025-2028.
- Revenue projections indicate steady growth, reaching around $2 billion globally by 2025.
- Competitive dynamics and regulatory developments will shape future pricing and market share.
FAQs
1. What is the global market size for ALK inhibitors?
The global NSCLC targeted therapy market was valued at $23.6 billion in 2022, with ALK inhibitors representing a significant segment.
2. How does Alecensa compare in efficacy to its competitors?
Alecensa shows superior CNS penetration and progression-free survival benefits over first-generation inhibitors like Crizotinib, leading to increased adoption.
3. What factors could lead to pricing reductions for Alecensa?
Introduction of biosimilars post-patent expiry, increased competition, and payer negotiations could reduce prices.
4. Are there upcoming regulatory changes that could affect the market?
Yes, expansion of indications to earlier lines of therapy and adjuvant settings could expand the patient base and impact pricing.
5. What is the expected timeline for patent expiry and generic entry?
Patent protection is expected to last until 2025-2028, with generics potentially entering markets shortly thereafter.
References
- IQVIA, EvaluatePharma (2022). Oncology Market Reports.
- U.S. Food and Drug Administration (2017, 2020). Alecensa approvals and indications.
- MarketWatch, Pharma Intelligence (2022). Targeted Lung Cancer Market Data.
